Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

Jacques Ferlay, Murielle Colombet, Isabelle Soerjomataram et al. · International Journal of Cancer · 2018 · 7.6K citations · Full text

Global Cancer Incidence, Cancer Management, Epidemiology Of Cancer +20

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.2K citations · Full text

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.4K citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor, Andrew J. Rech, Amit Maity et al. · Nature · 2015 · 2.3K citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +9

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Least Two +8